Vaxart VXA-CoV2-1 COVID-19 Oral Vaccine Description
Vaxart announced the initiation of a program to develop an oral vaccine VXA-CoV2-1 targeting the novel coronavirus SARS-CoV-2.
Vaxart oral recombinant vaccines are formulated as tablets that are enterically coated for efficient delivery to the small bowel. The enteric coating protects the active ingredient from the acidic environment in the stomach.
By targeting the small bowel, the vaccines engage the finely-tuned immune system of the gut to generate broad systemic and mucosal immune responses for robust, persistent immunity.
Vaxart is currently developing a liquid formulation for young children and adults who are unable to ingest tablets. Vaxart vaccines do not contain whole killed or attenuated viruses. No eggs are used in the production process.
Vaxart’s oral vaccines represent an important advance in vaccination technology. They are designed to generate broad and durable immune responses, including mucosal and systemic responses. The oral route of administration provides a more efficient and convenient method of administration relative to injectable vaccines.
On May 20, 2020, Sean Tucker, Ph.D., chief scientific officer of Vaxart, announced “In a phase 2 efficacy study, we have demonstrated that our oral H1 flu tablet vaccine protected against influenza infection after just 1-dose. Based on these results, we believe our vaccines are ideal to protect against mucosal respiratory viruses such as SARS-CoV-2, the virus that causes COVID-19.”
“The results of our recently published influenza challenge study demonstrated that our oral tablet vaccine primarily protects through mucosal immunity, a potential key factor when targeting mucosal pathogens, such as this new coronavirus,” said Sean Tucker, Ph.D. chief scientific officer of Vaxart.
This was a Phase 2 Randomized, Placebo- and Active-Controlled, Human Influenza A/California/04/2009 (H1N1) Challenge Study Following Administration of an Oral H1N1 HA Adenoviral-Vector Based Seasonal Influenza Vaccine and dsRNA Adjuvant (VXA-A1.1) to Healthy Adult Volunteers, which was last updated on July 26, 2018.
On August 6, 2020, Andrei Floroiu, chief executive officer of Vaxart, stated: “We believe the convenience of our oral tablet, coupled with the potential for better protection than that of injectable vaccines due to the activation of mucosal immunity, positions our COVID-19 vaccine as one of the most promising candidates for successful mass vaccination campaigns, both here in the US and abroad.”
On September 6, 2020, the non-peer-reviewed study 'Pre-clinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection' was published. These researchers stated: 'We demonstrate that, compared to the expression of the S1 domain or a stabilized spike antigen, the full length, wild-type spike antigen induces significantly higher neutralizing antibodies in the periphery and in the lungs, when the vaccine is administered mucosally. Antigen-specific CD4+ and CD8+ T cells were induced by this leading vaccine candidate at low and high doses. This full-length spike antigen plus nucleocapsid adenovirus construct has been prioritized for further clinical development.'
On October 14, 2020 - Vaxart announced the topline results from its Hamster Challenge Study that all hamsters that received (2) oral doses of COVID-19 vaccine candidate showed no systemic weight loss, a key indicator of protection against COVID-19 in this animal model. The study evaluated Vaxart’s recombinant adenoviral vaccine, with doses given at 0 and 4 weeks. Animals were challenged with SARS-CoV-2 at week 8.
These topline data demonstrated that all unvaccinated animals lost at least 8% of their body weight, and all showed evidence of lung disease as measured by relative weight gain in the lungs. By contrast, all animals vaccinated with 2-doses of the oral vaccine maintained or gained body weight by the end of the experiment, a statistically significant result (p<0.001).
Additionally, these animals were protected against the lung weight gain seen in the unvaccinated animals (p<0.001).
Vaxart is primarily focused on developing oral recombinant protein vaccines based on its proprietary oral vaccine platform. This development effort is based on the oral vaccine platform, VAAST, that employs a modular approach using a replication-incompetent adenovirus type 5 (Ad5) vector that delivers two payloads to the cells of the mucosal epithelium of the small bowel. One payload is the gene coding for the selected pathogen-specific protein antigen.
The other payload, which is always co-delivered, is the gene coding for the Toll-Like Receptor-3 (TLR-3) agonist, an adjuvant that activates the innate immune system, and was selected for its ability to stimulate broad immune responses. Every vaccine contains the TLR-3 adjuvant component.
For more information, please visit www.vaxart.com.
Vaxart VXA-CoV2-1 COVID-19 Oral Vaccine Indication
This COVID-19 Oral vaccine candidate tablet is indicated to prevent the new SARS-CoV-2 coronavirus, which causes COVID-19 disease in humans.
In preclinical testing, all animals that received one of the Vaxart vaccines had IgG anti-SARS CoV-2 antibodies in serum two weeks after the first vaccination. Antibody responses in all vaccinated groups were statistically significant compared to the untreated controls.
Vaxart plans to select one or more vaccine candidates for cGMP manufacturing and clinical testing based on the magnitude and the breadth of the immune response. Vaxart’s oral recombinant vaccine candidate is based on its proprietary VAAST™ platform.
Vaxart VXA-CoV2-1 COVID-19 Oral Vaccine News
October 17, 2020 - Hagens Berman announces that it has filed a class-action lawsuit against Vaxart, Inc. and certain of its senior executives and updates investors. The class action, filed in the United States District Court for the Northern District of California, Case No. 3:20-cv-05949-VC, is brought on behalf of investors who purchased or otherwise acquired securities between June 25, 2020, and July 25, 2020.
October 14, 2020 - Vaxart, Inc. announced the topline results from its Hamster Challenge Study.
October 13, 2020 - Vaxart announced that the first subject has been dosed in its Phase 1 study of VXA-CoV2-1, an oral tablet COVID-19 vaccine candidate.
October 13, 2020 - Vaxart's recent SEC filing disclosed that 'in July 2020, Vaxart was served with a Grand Jury Subpoena from the U.S. District Court for the Northern District of California, in connection with an investigation by the Office of the U.S. Attorney for the Northern District of California (“U.S. Attorney’s Office”). The Company has provided documents called for by the subpoena, which broadly pertain to the Company’s participation in, and disclosure of, an Operation Warp Speed (“OWS”)-funded nonhuman primate study, and option grants, warrant transactions, and other corporate and financing matters disclosed since March 2020. We are cooperating with the U.S. Attorney’s Office regarding these requests and have provided documents and information in response. And, in August 2020, the Enforcement Division of the Commission requested that the Company provide, on a voluntary basis, a variety of documents that broadly pertain to the same subject matters of the documents provided to the U.S. Attorney’s Office, and related matters. The Company has voluntarily provided documents requested by the SEC and is cooperating with this informal inquiry.'
September 14, 2020 - Vaxart announced that the U.S. FDA has completed its review of the Company’s Investigational New Drug application for its Phase 1 clinical trial evaluating its oral COVID-19 vaccine candidate.
September 8, 2020 - Vaxart, Inc. announced pre-publication of a manuscript titled “Preclinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection.” Andrei Floroiu, chief executive officer of Vaxart stated: “Cold storage distribution and the need for medical personnel as well as having to travel to vaccination sites and dislike of needles pose significant barriers to the vaccine uptake required for successful mass vaccination campaigns. We believe our room temperature stable, easy to administer oral vaccine provides a unique solution that overcomes these important difficulties."
September 3, 2020 - Vaxart, Inc. announced senior management will participate in conferences during September and invites investors to participate by webcast.
August 10, 2020 - Vaxart announced that its COVID-19 Investigational New Drug application has been filed with the U.S. FDA.
August 6, 2020 - Vaxart, Inc. provided an update on its financials for the second quarter of 2020 and a corporate update.
July 14, 2020 - Some experts say a vaccine puffed in the nose would be better at protecting people from infection.
June 26, 2020 - Vaxart, Inc. announced that its oral COVID-19 vaccine has been selected to participate in a non-human primate challenge study, organized and funded by Operation Warp Speed, a new national program aiming to provide substantial quantities of safe, effective vaccines for Americans by January 2021.
May 20, 2020 - Sean Tucker, Ph.D., chief scientific officer of Vaxart said: “In a phase 2 efficacy study that was recently published in the Lancet Infectious Diseases, we have demonstrated that our oral H1 flu tablet vaccine protected against influenza infection after just one dose. Based on these results, we believe our vaccines are ideal to protect against mucosal respiratory viruses such as SARS-CoV-2, the virus that causes COVID-19.”
May 20, 2020 - Kindred Biosciences, Inc. announced it has entered into an agreement with Vaxart, Inc. for the manufacture of Vaxart’s oral vaccine candidate for COVID-19. KindredBio will produce the candidate vaccine bulk drug substance under Good Manufacturing Practices, and provide it to Vaxart to be formulated into a vaccine tablet to be taken by mouth instead of by needle injection. KindredBio will manufacture the vaccine for clinical trials beginning in the second half of 2020.
May 14, 2020 - Coronavirus vaccine taken by tablet instead of injection is about to go into human trials.
May 12, 2020 - Vaxart, Inc. provided a corporate update. “In January we pivoted to COVID-19, and we are now on track to start the first Phase 1 study in the second half of this year with our oral tablet vaccine,” said Wouter Latour, MD, chief executive officer of Vaxart. “We are developing a state-of-the-art gene-based vaccine utilizing our proprietary vector platform, and the lead candidate vaccines performed well in preclinical testing, generating very high levels of antibodies.”
April 21, 2020 - Vaxart announced that it has obtained positive pre-clinical results for its COVID-19 vaccine candidates, with several of the vaccine candidates generating immune responses in all tested animals after a single dose.
March 18, 2020 - Vaxart announced that it has entered into an agreement with Emergent BioSolutions Inc., whereby Emergent will deploy its molecule-to-market contract development and manufacturing services to help develop and manufacture Vaxart’s experimental oral vaccine candidate for coronavirus disease-19 (COVID-19).
January 31, 2020 - Vaxart, Inc. announced today that it has initiated a program to develop a coronavirus vaccine candidate based on its proprietary oral vaccine platform, VAAST.
September 1, 2015 - Study: High-titer neutralizing antibodies to influenza after oral tablet immunization: a phase 1, randomized, placebo-controlled trial.
2014 - Vaxart, Inc., announced clinical results demonstrating that its H1N1 tablet vaccine generates protective immunity comparable to currently licensed influenza vaccines, as measured by hemagglutinin inhibition assay (HAI), the established correlate of protection. Vaxart’s founder and chief scientific officer, Sean Tucker, Ph.D., discussed the data in a presentation today at the 15th Annual World Vaccine Congress in Brussels.
Vaxart VXA-CoV2-1 COVID-19 Oral Vaccine Clinical Trial
ClinicalTrials.gov Identifier: NCT04563702 - Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults. Last Update Posted: September 28, 2020.
The Phase 1, open-label, dose-ranging trial is designed to examine the safety and immunogenicity of two doses of VXA-CoV2-1 in up to 48 healthy adult volunteers aged 18 to 54 years old. Enrollment is expected to be completed by early November 2020, with participants receiving the low or high dose of the VXA-CoV2-1 oral tablet at days 1 and 29. Safety, reactogenicity and immunogenicity assessments will be performed at set times during the active phase.